Oxford BioTherapeutics
  • ABOUT
    • OUR TEAM
    • BOARD OF DIRECTORS
    • INVESTORS
    • OFFICES & LABS
  • PIPELINES
    • INTERNAL PROGRAMS
    • PARTNERED PROGRAMS
  • PARTNERSHIPS
  • OUR SCIENCE
    • IO DISCOVERY PLATFORM >
      • IMMUNE CHECKPOINT TARGETS
      • IO ANTIBODY ENGINEERING
    • OGAP DISCOVERY PLATFORM
    • PUBLICATIONS
  • CAREERS
  • NEWS
    • PRESS RELEASES
    • OBT in the News
  • CONTACT

OGAP Discovery Platform

OGAP® Discovery Platform

OBT’s proprietary platform, OGAP®, is the world’s largest cancer specific membrane protein library, directly measuring plasma membrane protein expression in patient tumors. OGAP® characterises cell surface protein expression of tumours and healthy tissue to identify novel cell-surface cancer targets to develop first-in-class antibody drug conjugate (ADC), Bispecific T-cell Engager (BiTE®) and Chimeric Antigen Receptor (CAR) therapeutics.
 
OBT identified CD205 using OGAP®, a receptor overexpressed on tumor cells (gastric, lung & ovarian cancer) and some immune suppressive cells, leading to the development of OBT076, an ADC targeting CD205.
 
The platform enables access to a wide range of targets which can be leveraged in external partnerships with leaders in the oncology space. Existing partnerships include Boehringer Ingelheim and Kite.

Picture

Privacy Policy

Legal Notice

Site Map

© 2017 Oxford BioTherapeutics All Rights Reserved
  • ABOUT
    • OUR TEAM
    • BOARD OF DIRECTORS
    • INVESTORS
    • OFFICES & LABS
  • PIPELINES
    • INTERNAL PROGRAMS
    • PARTNERED PROGRAMS
  • PARTNERSHIPS
  • OUR SCIENCE
    • IO DISCOVERY PLATFORM >
      • IMMUNE CHECKPOINT TARGETS
      • IO ANTIBODY ENGINEERING
    • OGAP DISCOVERY PLATFORM
    • PUBLICATIONS
  • CAREERS
  • NEWS
    • PRESS RELEASES
    • OBT in the News
  • CONTACT